Evaluation of the anticancer effects exerted by 5-fluorouracil and heme oxygenase-1 inhibitor hybrids in HTC116 colorectal cancer cells

References

• Surh YJ, Chung HT, Na HK, Dulak J, Stec DE. Progress in heme oxygenase research. Arch Biochem Biophys. 2020;685:1.
   Web of Science ®Google Scholar
• Intagliata S, Salerno L, Ciaffaglione V, Leonardi C, Fallica AN, Carota G, Amata E, Marrazzo A, Pittalà V, Romeo G. Heme oxygenase-2 (ho-2) as a therapeutic target: activators and inhibitors. Eur J Med Chem. 2019;183:111703.
   PubMed Web of Science ®Google Scholar
• Salerno L, Floresta G, Ciaffaglione V, Gentile D, Margani F, Turnaturi R, Rescifina A, Pittalà V. Progress in the development of selective heme oxygenase-1 inhibitors and their potential therapeutic application. Eur J Med Chem. 2019;167:439–10.
   PubMed Web of Science ®Google Scholar
• Luu Hoang KN, Anstee JE, Arnold JN. The diverse roles of heme oxygenase-1 in tumor progression. Front Immunol. 2021;12:658315.
   PubMed Web of Science ®Google Scholar
• Ciaffaglione V, Intagliata S, Pittalà V, Marrazzo A, Sorrenti V, Vanella L, Rescifina A, Floresta G, Sultan A, Greish K, et al. New arylethanolimidazole derivatives as ho-1 inhibitors with cytotoxicity against mcf-7 breast cancer cells.  Int J Mol Sci. 2020;21(6):21.
   Web of Science ®Google Scholar
• Mucha O, Podkalicka P, Mikulski M, Barwacz S, Andrysiak K, Biela A, Mieczkowski M, Kachamakova-Trojanowska N, Ryszawy D, Białas A, et al. Development and characterization of a new inhibitor of heme oxygenase activity for cancer treatment. Arch Biochem Biophys. 2019;671:130–142.
   PubMed Web of Science ®Google Scholar
• Fallica AN, Sorrenti V, D’Amico AG, Salerno L, Romeo G, Intagliata S, Consoli V, Floresta G, Rescifina A, D’Agata V, et al. Discovery of novel acetamide-based heme oxygenase-1 inhibitors with potent in vitro antiproliferative activity. J Med Chem. 2021;64(18):13373–13393.
   PubMed Web of Science ®Google Scholar
• Romeo G, Ciaffaglione V, Amata E, Dichiara M, Calabrese L, Vanella L, Sorrenti V, Grosso S, D’Amico AG, D’Agata V, et al. Combination of heme oxygenase-1 inhibition and sigma receptor modulation for anticancer activity. Molecules. 2021; 26(13):3860.
   PubMed Web of Science ®Google Scholar
• Sorrenti V, Pittalà V, Romeo G, Amata E, Dichiara M, Marrazzo A, Turnaturi R, Prezzavento O, Barbagallo I, Vanella L, et al. Targeting heme oxygenase-1 with hybrid compounds to overcome imatinib resistance in chronic myeloid leukemia cell lines. Eur J Med Chem. 2018;158(:937–950.
   PubMed Web of Science ®Google Scholar
• Torp SH, Solheim O, Skjulsvik AJ. The who 2021 classification of central nervous system tumours: A practical update on what neurosurgeons need to know-a minireview. Acta Neurochir (Wien)). 2022;164(9):2453–2464.
   PubMed Web of Science ®Google Scholar
• Yin H, Fang J, Liao L, Maeda H, Su Q. Upregulation of heme oxygenase-1 in colorectal cancer patients with increased circulation carbon monoxide levels, potentially affects chemotherapeutic sensitivity. BMC Cancer. 2014;14(1):436. (
   PubMedGoogle Scholar
• Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, Smith A, Bordner J, Polte T, Gaunitz F, et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem. 2007;282(28):20621–20633.
   PubMed Web of Science ®Google Scholar
• NIH. Drugs approved for colon and rectal cancer National Cancer institute:Updated: January 23, 2023 (Cited: October 14,23.
   Google Scholar
• Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–117.
   PubMed Web of Science ®Google Scholar
• Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol. 2016;8(1):57–84.
   PubMed Web of Science ®Google Scholar
• World health organization. Model list of essential medicines - 23rd list. 2023. WHO: Geneva.:Retrieved 14 October 2023 from https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1(.
   Google Scholar
• Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009;109(7):2880–2893.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215–237.
   PubMed Web of Science ®Google Scholar
• Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol. 2000;1(2):137–164.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338.
   PubMed Web of Science ®Google Scholar
• Macdonald JS. Toxicity of 5-fluorouracil. Oncology (Williston Park). 1999;13(7 Suppl 3):33–34.
   PubMed Web of Science ®Google Scholar
• Shiga T, Hiraide M. Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr Treat Options Oncol. 2020;21(4):27.
   PubMed Web of Science ®Google Scholar
• Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980;40(7):2223–2228.
   PubMed Web of Science ®Google Scholar
• Mohelnikova-Duchonova B, Melichar B, Soucek P. Folfox/folfiri pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol. 2014;20(30):10316–10330.
   PubMed Web of Science ®Google Scholar
• de Oliveira Pedrosa M, Duarte da Cruz RM, de Oliveira Viana J, de Moura RO, Ishiki HM, Barbosa Filho JM, Diniz MF, Scotti MT, Scotti L, Bezerra Mendonca FJ. Hybrid compounds as direct multitarget ligands: a review. Curr Top Med Chem. 2017;17(9):1044–1079.
   PubMed Web of Science ®Google Scholar
• Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK. Codrug: An efficient approach for drug optimization. Eur J Pharm Sci. 2010;41(5):571–588.
   PubMed Web of Science ®Google Scholar
• Ciaffaglione V, Modica MN, Pittalà V, Romeo G, Salerno L, Intagliata S. Mutual prodrugs of 5-fluorouracil: From a classic chemotherapeutic agent to novel potential anticancer drugs. ChemMedChem. 2021;16(23):3496–3512.
   PubMed Web of Science ®Google Scholar
• Salerno L, Vanella L, Sorrenti V, Consoli V, Ciaffaglione V, Fallica AN, Canale V, Zajdel P, Pignatello R, Intagliata S. Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-fu/ho-1 hybrid): Design and preliminary in vitro evaluation. J Enzyme Inhib Med Chem. 2021;36(1):1378–1386.
   PubMed Web of Science ®Google Scholar
• Salerno L, Sorrenti V, Pittalà V, Consoli V, Modica MN, Romeo G, Marrazzo A, Giuliano M, Zajdel P, Vanella L, et al. Discovery of si 1/20 and si 1/22 as mutual prodrugs of 5-fluorouracil and imidazole-based heme oxygenase 1 inhibitor with improved cytotoxicity in du145 prostate cancer cells. ChemMedChem. 2023;18(8):e202300047.
   PubMed Web of Science ®Google Scholar
• Akhdar H, Loyer P, Rauch C, Corlu A, Guillouzo A, Morel F. Involvement of nrf2 activation in resistance to 5-fluorouracil in human colon cancer ht-29 cells. Eur J Cancer. 2009;45(12):2219–2227.
   PubMed Web of Science ®Google Scholar
• Cernigliaro C, D’Anneo A, Carlisi D, Giuliano M, Marino Gammazza A, Barone R, Longhitano L, Cappello F, Emanuele S, Distefano A, et al. Ethanol-mediated stress promotes autophagic survival and aggressiveness of colon cancer cells via activation of nrf2/ho-1 pathway. Cancers (Basel). 2019;11(4):11.
   Web of Science ®Google Scholar
• Seo GS, Jiang WY, Chi JH, Jin H, Park WC, Sohn DH, Park PH, Lee SH. Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity. Oncotarget. 2015;6(23):19792–19806.
   PubMedGoogle Scholar
• Lo Galbo V, Lauricella M, Giuliano M, Emanuele S, Carlisi D, Calvaruso G, De Blasio A, Di Liberto D, D’Anneo A. Redox imbalance and mitochondrial release of apoptogenic factors at the forefront of the antitumor action of mango peel extract. Molecules. 2021; 26(14):4328.
   PubMed Web of Science ®Google Scholar
• Notaro A, Lauricella M, Di Liberto D, Emanuele S, Giuliano M, Attanzio A, Tesoriere L, Carlisi D, Allegra M, De Blasio A, et al. A deadly liaison between oxidative injury and p53 drives methyl-gallate-induced autophagy and apoptosis in hct116 colon cancer cells. Antioxidants (Basel). 2023;12(6):12.
   Google Scholar
• Salerno L, Amata E, Romeo G, Marrazzo A, Prezzavento O, Floresta G, Sorrenti V, Barbagallo I, Rescifina A, Pittalà V. Potholing of the hydrophobic heme oxygenase-1 western region for the search of potent and selective imidazole-based inhibitors. Eur J Med Chem. 2018;148(:54–62.
   PubMed Web of Science ®Google Scholar
• Greish KF, Salerno L, Al Zahrani R, Amata E, Modica MN, Romeo G, Marrazzo A, Prezzavento O, Sorrenti V, Rescifina A, et al. Novel structural insight into inhibitors of heme oxygenase-1 (ho-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation. Molecules. 2018;23(5):1209.
   PubMed Web of Science ®Google Scholar
• Lauricella M, D’Anneo A, Giuliano M, Calvaruso G, Emanuele S, Vento R, Tesoriere G. Induction of apoptosis in human osteosarcoma saos-2 cells by the proteasome inhibitor mg132 and the protective effect of prb. Cell Death Differ. 2003;10(8):930–932.
   PubMed Web of Science ®Google Scholar
• Celesia A, Morana O, Fiore T, Pellerito C, D’Anneo A, Lauricella M, Carlisi D, De Blasio A, Calvaruso G, Giuliano M, et al. Ros-dependent er stress and autophagy mediate the anti-tumor effects of tributyltin (iv) ferulate in colon cancer cells. Int J Mol Sci. 2020;21(21):21.
   Web of Science ®Google Scholar
• Rahman MN, Vlahakis JZ, Vukomanovic D, Szarek WA, Nakatsu K, Jia Z. X-ray crystal structure of human heme oxygenase-1 with (2r,4s)-2-[2-(4-chlorophenyl)ethyl]-2-[(1h-imidazol-1-yl)methyl]-4[((5-trifluoromethylpyridin-2-yl)thio)methyl]-1,3-dioxolane: A novel, inducible binding mode. J Med Chem. 2009;52(15):4946–4950.
   PubMed Web of Science ®Google Scholar
• Fu Y, Yang G, Zhu F, Peng C, Li W, Li H, Kim HG, Bode AM, Dong Z, Dong Z. Antioxidants decrease the apoptotic effect of 5-fu in colon cancer by regulating src-dependent caspase-7 phosphorylation. Cell Death Dis. 2014;5(1):e983–e983.
   PubMedGoogle Scholar
• Emanuele S, Celesia A, D’Anneo A, Lauricella M, Carlisi D, De Blasio A, Giuliano M. The good and bad of nrf2: An update in cancer and new perspectives in covid-19. Int J Mol Sci. 2021;(15):22.
   PubMed Web of Science ®Google Scholar
• Pandey A, Trigun SK. Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (nrf2). J Cell Biochem. 2023;124(9):1289–1308.
   PubMed Web of Science ®Google Scholar
• Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci. 2019;134(:116–137.
   PubMed Web of Science ®Google Scholar